Document:

EX-10.45

 Exhibit 10.45 

Confidential 
 CYTOKINETICS, INCORPORATED

 COMMON STOCK PURCHASE AGREEMENT 

THIS COMMON STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of February 1, 2017 (the “Execution
Date”) by and between Cytokinetics, Incorporated, a Delaware corporation (the “Company”), and RPI Finance Trust, a Delaware statutory trust (the “Investor”). 

RECITALS 
 WHEREAS,
the Company and the Investor have entered into that certain Royalty Purchase Agreement by and between the Company and the Investor of even date herewith (the “Royalty Purchase Agreement”); 

WHEREAS, pursuant to terms set forth in this Agreement the Company desires to sell to the Investor, and the Investor desires to
purchase from the Company, shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”); 

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 SECTION 1 

Purchase and Sale of Shares 

1.1 Sale of Shares. Subject to the terms and conditions hereof and of the Royalty Purchase Agreement, the Company will issue and
sell to the Investor, and the Investor will purchase from the Company, at the Closing (as defined below), 875,656 shares of Common Stock (the “Shares”) for a total purchase price of Nine Million Nine Hundred Ninety-Nine Thousand Nine
Hundred Ninety-One Dollars and Fifty-Two Cents ($9,999,991.52) (the “Aggregate Purchase Price”). 
 1.2
Closing. The purchase and sale of the Shares shall take place at a closing (the “Closing”) to be held at the offices of Cooley LLP, 3175 Hanover Street, Palo Alto, California 94304-1130, on the Closing Date set forth
in the Royalty Purchase Agreement, or such other time as agreed by both parties (the “Closing Date”). At the Closing, the Company will deliver or cause to be delivered to the Investor a certificate or certificates representing the
Shares that the Investor is purchasing and, concurrently, the Investor shall pay the Aggregate Purchase Price by (a) check payable to the Company, (b) wire transfer in accordance with the Company’s instructions, or (c) any
combination of the foregoing. 

  
 1 

 Confidential 
  

 SECTION 2 

Representations and Warranties of the Company 

Except as set forth on the Schedule of Exceptions attached hereto as Exhibit A, the Company hereby represents and warrants
the following as of the Execution Date: 
 2.1 Organization and Good Standing and Qualifications. The Company is a corporation
duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite power and authority to own, lease, operate and occupy its properties and to carry on its business as now being conducted. Except as
set forth on the Schedule of Exceptions, the Company does not own more than 50% of the outstanding capital stock of or control any other business entity. The Company is duly qualified as a foreign corporation to do business and is in good
standing in every jurisdiction in which the nature of the business conducted or property owned or leased by it makes such qualification necessary, other than those in which the failure so to qualify or be in good standing would not have a Material
Adverse Effect. For purposes of this Agreement, “Material Adverse Effect” shall mean any event or condition that would reasonably be likely to have a material adverse effect on the business, operations, properties or financial
condition of the Company and its consolidated subsidiaries, taken as a whole, or adversely affect in any material respect the ability of the Company to perform its obligations, or Investor’s rights, under the Royalty Purchase Agreement;
provided, that none of the following shall constitute a “Material Adverse Effect”: the effects of conditions or events that are generally applicable to the capital, financial, banking or currency markets and the biotechnology
industry, and changes in the market price of the Common Stock. 
 2.2 Authorization. (i) The Company has the requisite
corporate power and authority to enter into and perform its obligations under this Agreement; (ii) the execution and delivery of this Agreement by the Company, the consummation by the Company of the transactions contemplated hereby and thereby
and the issuance, sale and delivery of the Shares have been duly authorized by all necessary corporate action and no further consent or authorization of the Company or its Board of Directors or stockholders is required; and (iii) the Agreement
has been duly executed and delivered and constitutes a valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, securities,
insolvency, or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies, or indemnification or by other equitable principles of general application. 

2.3 Valid Issuance of Shares. The issuance of the Shares has been duly authorized by all requisite corporate action. When the
Shares are issued, sold and delivered in accordance with the terms of this Agreement for the consideration expressed herein, the Shares will be duly and validly issued and outstanding, fully paid, and nonassessable, and will be free of all liens and
restrictions on transfer other than restrictions on transfer under this Agreement and under applicable state and federal securities laws and except as set forth in this Agreement the Investor shall be entitled to all rights accorded to a holder of
shares of Common Stock. The Company has reserved a sufficient number of shares of Common Stock for issuance to the Investor in accordance with the Company’s obligations under this Agreement. 

  
 2 

 Confidential 
  

 2.4 No Conflict. The execution, delivery and performance of this Agreement, and
any other document or instrument contemplated hereby, by the Company and the consummation by the Company of the transactions contemplated hereby, do not: (i) violate any provision of the Certificate or Bylaws, (ii) conflict with, or
constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any material agreement, mortgage, deed of trust,
indenture, note, bond, license, lease agreement, instrument or obligation to which the Company is a party where such default or conflict would constitute a Material Adverse Effect, (iii) create or impose a lien, charge or encumbrance on any
property of the Company under any agreement or any commitment to which the Company is a party or by which the Company is bound, which would constitute a Material Adverse Effect, (iv) result in a violation of any federal, state, local or foreign
statute, rule, regulation, order, writ, judgment or decree (including federal and state securities laws and regulations) applicable to the Company or any of its subsidiaries or by which any property or asset of the Company are bound or affected
where such violation would constitute a Material Adverse Effect, or (v) require any consent of any third-party that has not been obtained pursuant to any material contract to which the Company is subject or to which any of its assets,
operations or management may be subject where the failure to obtain any such consent would constitute a Material Adverse Effect. The Company is not required under federal, state or local law, rule or regulation to obtain any consent, authorization
or order of, or make any filing or registration with, any court or governmental agency in order for it to execute, deliver or perform any of its obligations under this Agreement or issue and sell the Shares in accordance with the terms hereof (other
than any filings that may be required to be made by the Company with the Securities and Exchange Commission (the “Commission”), the National Association of Securities Dealers, Inc./Nasdaq or state securities commissions subsequent
to the Closing); provided that, for purposes of the representation made in this sentence, the Company is assuming and relying upon the accuracy of the relevant representations and agreements of the Investor herein. 

2.5 Compliance. The Company is not, and the execution and delivery of this Agreement and the consummation of the transactions
contemplated herewith will not cause the Company to be (i) in violation or default of any provision of any instrument, mortgage, deed of trust, loan, contract, commitment filed with the Commission Documents (as defined below), (ii) in
violation of any provision of any judgment, decree, order or obligation to which it is a party or by which it or any of its properties or assets are bound, or (iii) in violation of any federal, state or, to its knowledge, local statute, rule or
governmental regulation, in the case of each of clauses (i), (ii) and (iii), which would have a Material Adverse Effect. 
 2.6
Capitalization. As of December 14, 2016 (the “Reference Date”), a total of 40,615,610 shares of Common Stock were issued and outstanding, increased as set forth in the next sentence. Other than in the ordinary
course of business, the Company has not issued any capital stock since the Reference Date other than pursuant to (i) employee benefit plans disclosed in the Commission Documents, and (ii) outstanding warrants, options or other securities
disclosed in the Commission Documents. The outstanding shares of capital stock of the Company have been duly and validly issued and are fully paid and nonassessable, were not issued in violation of any preemptive rights or similar rights to
subscribe for or purchase securities, and, for those shares issued until the Closing, have been issued in compliance with all federal and state securities laws, in 

  
 3 

 Confidential 
  

 
each case except as would not reasonably be expected to have a Material Adverse Effect. Except as set forth in the Commission Documents, there are no outstanding rights (including, without
limitation, preemptive rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any unissued shares of capital stock or other equity interest in the Company, or any contract, commitment, agreement, understanding
or arrangement of any kind to which the Company is a party and relating to the issuance or sale of any capital stock of the Company, any such convertible or exchangeable securities or any such rights, warrants or options. Without limiting the
foregoing, no preemptive right, co-sale right, right of first refusal, registration right, or other similar right exists with respect to the Shares or the issuance and sale thereof. There are no shareholder agreements, voting agreements or other
similar agreements with respect to the voting of the Shares to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s shareholders. 

2.7 Commission Documents, Financial Statements. The Company’s Common Stock is registered pursuant to Section 12(b) or
12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and during the past twelve (12) months the Company has timely filed all reports, schedules, forms, statements and other documents required to be
filed by it with the Commission pursuant to the reporting requirements of the Exchange Act, including material filed pursuant to Section 13(a) or 15(d) of the Exchange Act (all of the foregoing, including filings incorporated by reference
therein, being referred to herein as the “Commission Documents”). The Company’s Common Stock is currently listed or quoted on the NASDAQ Market. The Company is not in violation of the listing requirements of the NASDAQ Market
and has no knowledge of any facts that would reasonably lead to delisting or suspension of its common stock from NASDAQ in the foreseeable future. As of its date, each Commission Document filed within the past twelve (12) months for the year
ended December 31, 2016 complied in all material respects with the requirements of the Exchange Act and the rules and regulations of the Commission promulgated thereunder applicable to such document, and, as of its date, after giving effect to
the information disclosed and incorporated by reference therein, no such Commission Document within the past twelve (12) months contained any untrue statement of a material fact or omit to state a material fact required to be stated therein or
necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. As of their respective dates, the financial statements of the Company included in the Commission Documents filed with the
Commission during the past twelve months complied as to form and substance in all material respects with applicable accounting requirements and the published rules and regulations of the Commission or other applicable rules and regulations with
respect thereto. Such financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) applied on a consistent basis during the periods involved (except (i) as may be otherwise
indicated in such financial statements or the notes thereto or (ii) in the case of unaudited interim statements, to the extent they may not include footnotes or may be condensed or summary statements), and fairly present in all material
respects the financial position of the Company as of the dates thereof and the results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). 

  
 4 

 Confidential 
  

 2.8 Internal Controls and Procedures. The Company maintains disclosure controls
and procedures as such terms are defined in, and required by, Rule 13a-15 and Rule 15d-15 under the Exchange Act. Such disclosure controls and procedures are effective as of the latest date of management’s evaluation of such disclosure controls
and procedures as set forth in the Commission Documents to ensure that all material information required to be disclosed by the Company in the reports that it files or furnishes under the Exchange Act is recorded, processed, summarized and reported
within the time periods specified in the rules and forms of the Commission. The Company maintains a system of internal controls over financial reporting sufficient to provide reasonable assurance that (i) transactions are executed in accordance
with management’s general or specific authorizations; and (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP. 

2.9 Material Adverse Change. Except as disclosed in the Commission Documents, since September 30, 2016, no event or series
of events has or have occurred that would, individually or in the aggregate, have a Material Adverse Effect on the Company. 
 2.10 No
Undisclosed Liabilities. To the Company’s knowledge, neither the Company nor any of its subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued,
contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company or any of its subsidiaries (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other than those
incurred in the ordinary course of the Company’s or its subsidiaries’ respective businesses since September 30, 2016. 
 2.11
No Undisclosed Events or Circumstances. Except for the transactions contemplated by this Agreement and the Royalty Purchase Agreement, no event or circumstance has occurred or exists with respect to the Company, its subsidiaries, or
their respective businesses, properties, operations or financial condition, which, under applicable law, rule or regulation, requires public disclosure or announcement by the Company but which has not been so publicly announced or disclosed and
which, individually or in the aggregate, would have a Material Adverse Effect on the Company. 
 2.12 Actions Pending. There
is no action, suit, claim, investigation or proceeding pending or, to the knowledge of the Company, threatened against the Company or any subsidiary which questions the validity of this Agreement or the transactions contemplated hereby or any action
taken or to be taken pursuant hereto. Except as set forth in the Commission Documents or as previously disclosed in writing to the Investor, there is no action, suit, claim, investigation or proceeding pending or, to the knowledge of the Company,
threatened, against or involving the Company, any subsidiary, or any of their respective properties or assets that could be reasonably expected to have a Material Adverse Effect on the Company. Except as set forth in the Commission Documents or as
previously disclosed in writing to the Investor, no judgment, order, writ, injunction or decree or award has been issued by or, to the knowledge of the Company, requested of any court, arbitrator or governmental agency which could be reasonably
expected to result in a Material Adverse Effect. 

  
 5 

 Confidential 
  

 2.13 Compliance with Law. The businesses of the Company and its subsidiaries
have been and are presently being conducted in accordance with all applicable federal, state and local governmental laws, rules, regulations and ordinances, except as would not reasonably be expected to cause a Material Adverse Effect. The Company
and each of its subsidiaries have all franchises, permits, licenses, consents and other governmental or regulatory authorizations and approvals necessary for the conduct of its business as now being conducted by it, except for such franchises,
permits, licenses, consents and other governmental or regulatory authorizations and approvals, the failure to possess which, individually or in the aggregate, could not reasonably be expected to have a Material Adverse Effect. 

2.14 Exemption from Registration, Valid Issuance. Subject to, and in reliance on, the representations, warranties and covenants
made herein by the Investor, the issuance and sale of the Shares in accordance with the terms and on the bases of the representations and warranties set forth in this Agreement, may and shall be properly issued pursuant to Section 4(a)(2) of
the Securities Act of 1933, as amended (the “Securities Act”), Regulation D promulgated pursuant to the Act (“Regulation D”) and/or any other applicable federal and state securities laws. The sale and issuance
of the Shares pursuant to, and the Company’s performance of its obligations under, this Agreement will not (i) result in the creation or imposition of any liens, charges, claims or other encumbrances upon the Shares or any of the assets of
the Company, or (ii) entitle the holders of any outstanding shares of capital stock of the Company to preemptive or other rights to subscribe to or acquire the Shares or other securities of the Company. 

2.15 Transfer Taxes. All stock transfer or other taxes (other than income taxes) which are required to be paid in connection
with the sale and transfer of the Shares to be sold to Investor hereunder will be, or will have been, fully paid or provided for by the Company and all laws imposing such taxes will be or will have been fully complied with. 

2.16 Investment Company. The Company is not and, after giving effect to the offering and sale of the Shares, will not be an
“investment company” as defined in the Investment Company Act of 1940, as amended. 
 2.17 Brokers. Except as
expressly set forth in this Agreement or the Royalty Purchase Agreement, no brokers, finders or financial advisory fees or commissions will be payable by the Company or any of its subsidiaries in respect of the transactions contemplated by this
Agreement or the Royalty Purchase Agreement. 
 SECTION 3 

Representations and Warranties of the Investor 

The Investor hereby represents and warrants the following as of the date hereof and as of the Closing Date: 

3.1 Experience. The Investor is experienced in evaluating companies such as the Company, has such knowledge and experience in
financial and business matters that the Investor is capable of evaluating the merits and risks of the Investor’s prospective investment in the Company, and has the ability to bear the economic risks of the investment. 

  
 6 

 Confidential 
  

 3.2 Investment. The Investor is acquiring the Shares for investment for the
Investor’s own account and not with the view to, or for resale in connection with, any distribution thereof. The Investor understands that the Shares have not been and will not be registered under the Securities Act by reason of a specific
exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent as expressed herein. The Investor further represents that it does not have any contract,
undertaking, agreement or arrangement with any person to sell, transfer or grant participation to any third person with respect to any of the Shares. 

3.3 Rule 144. The Investor acknowledges that the Shares must be held indefinitely unless subsequently registered under the
Securities Act or an exemption from such registration is available. The Investor is aware of the provisions of Rule 144 promulgated under the Securities Act which permit limited resale of shares purchased in a private placement subject to the
satisfaction of certain conditions. In connection therewith, the Investor acknowledges that the Company will make a notation on its stock books regarding the restrictions on transfers set forth in this Section 3, subject to Section 7.2,
and will transfer the Shares on the books of the Company only to the extent not inconsistent herewith and therewith. 
 3.4 Access to
Information. The Investor has received and reviewed information about the Company and has had an opportunity to discuss the Company’s business, management and financial affairs with its management and to review the Company’s
facilities. The Investor has had a full opportunity to ask questions of and receive answers from the Company, or any person or persons acting on behalf of the Company, concerning the terms and conditions of an investment in the Shares. The Investor
is not relying upon, and has not relied upon, any statement, representation or warranty made by any person, except for the statements, representations and warranties contained in this Agreement and the Royalty Purchase Agreement. 

3.5 Authorization. This Agreement when executed and delivered by the Investor will constitute a valid and legally binding
obligation of the Investor, enforceable in accordance with its terms, subject to: (i) judicial principles respecting election of remedies or limiting the availability of specific performance, injunctive relief, and other equitable remedies; and
(ii) bankruptcy, insolvency, reorganization, moratorium or other similar laws now or hereafter in effect generally relating to or affecting creditors’ rights. 

3.6 Investor Status. The Investor acknowledges that it is either (i) an institutional “accredited investor” as
defined in Rule 501(a) of Regulation D of the Securities Act (an “Institutional Accredited Investor”) or (ii) a “qualified institutional buyer” as defined in Rule 144A of the Securities Act, as
indicated on Schedule A hereto, and the Investor shall submit to the Company such further assurances of such status as may be reasonably requested by the Company. 

3.7 No Inducement. The Investor was not induced to participate in the offer and sale of the Shares by the filing of any
registration statement in connection with any public offering of the Company’s securities, and the Investor’s decision to purchase the Shares hereunder was not influenced by the information contained in any such registration statement.

  
 7 

 Confidential 
  

 SECTION 4 

Conditions to Investor’s Obligations at Closing 

The obligations of the Investor under this Agreement are subject to the fulfillment on or before the Closing of each of the following
conditions, any of which may be waived in writing by the Investor (except to the extent not permitted by law): 
 4.1 No Injunction,
etc. No preliminary or permanent injunction or other binding order, decree or ruling issued by a court or governmental agency shall be in effect which shall have the effect of preventing the consummation of the transactions contemplated by
this Agreement. No action or claim shall be pending before any court or quasi-judicial or administrative agency of any federal, state, local or foreign jurisdiction or before any arbitrator wherein an unfavorable injunction, judgment, order, decree,
ruling or charge would be reasonably likely to (i) prevent consummation of any of the transactions contemplated by this Agreement, (ii) cause any of the transactions contemplated by this Agreement to be rescinded following consummation or
(iii) have the effect of making illegal the purchase of, or payment for, any of the Shares by the Investor. 
 4.2
Representations and Warranties. The representations and warranties of the Company contained in Section 2 shall have been true and correct in all material respects (except for such representations and warranties that are qualified
by “materiality” or “Material Adverse Effect” which shall be true and correct in all respects) on and as of the Execution Date with the same effect as though such representations and warranties had been made on and as of such
date. 
 4.3 Performance. The Company shall have performed and complied with all covenants, agreements, obligations and
conditions contained in this Agreement that are required to be performed or complied with by it on or before the Execution Date. 
 4.4
Compliance Certificate. A duly authorized officer of the Company shall deliver to the Investor at the Closing a certificate stating that the conditions specified in Sections 4.2 and 4.3 have been fulfilled and certifying and
attaching the Company’s Certificate of Incorporation, Bylaws and authorizing Board of Directors resolutions with respect to this Agreement, the Royalty Purchase Agreement and the transactions contemplated hereby and thereby. 

4.5 Securities Laws. The offer and sale of the Shares to the Investor pursuant to this Agreement shall be exempt from the
registration requirements of the Securities Act and the registration and/or qualification requirements of all applicable state securities laws. 

4.6 Authorizations. All authorizations, approvals or permits, if any, of any governmental authority or regulatory body that are
required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall have been duly obtained and shall be effective on and as of the Closing. 

4.7 Legal Opinion. The Investor shall have received a legal opinion from Cooley LLP in form and substance reasonably
acceptable to the Investor. 

  
 8 

 Confidential 
  

 4.8 Purchase of Royalty. The transactions under the Royalty Purchase Agreement
shall have been consummated. 
 SECTION 5 

Conditions to the Company’s Obligations at Closing 

The obligations of the Company to the Investor under this Agreement are subject to the fulfillment on or before the Closing of each of the
following conditions by the Investor: 
 5.1 Representations and Warranties. The representations and warranties of the Investor
contained in Section 3 shall be true and correct in all material respects (except for such representations and warranties that are qualified by materiality which shall be true and correct in all respects) on and as of the Closing with the same
effect as though such representations and warranties had been made on and as of the Closing. 
 5.2 Securities Law Compliance.
The offer and sale of the Shares to the Investor pursuant to this Agreement shall be exempt from the registration requirements of the Securities Act and the registration and/or qualification requirements of all applicable state securities laws. 

5.3 Authorization. All authorizations, approvals or permits, if any, of any governmental authority or regulatory body
that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall have been duly obtained and shall be effective on and as of the Closing. 

5.4 Purchase of Royalty. The transactions under the Royalty Purchase Agreement shall have been consummated. 

SECTION 6 
 Investor
Covenants 
 6.1 Trading Restrictions. 

(a) Definitions. 
 (i)
“Affiliate” shall have the meaning set forth in Rule 12b-2 of the regulations promulgated under the Securities Exchange Act of 1934, as amended. 

(ii) “Restriction Period” shall mean the period commencing on the Closing Date and continuing until the one year anniversary
of the Closing Date. 

  
 9 

 Confidential 
  

 (iii) “Significant Event” shall mean any of the following not involving a
violation of this Section 6: (A) the public announcement of a proposal or intention to acquire, or the acquisition, by any person or 13D Group of beneficial ownership of Voting Securities representing 15% or more of the then outstanding
Voting Securities; (B) the public announcement of a proposal or intention to commence, or the commencement, by any person or 13D Group of a tender or exchange offer to acquire Voting Securities which, if successful, would result in such person
or 13D Group owning, when combined with any other Voting Securities owned by such person or 13D Group, 15% or more of the then outstanding Voting Securities; or (C) the entry into by the Company, or the public announcement by the Company of an
intention or determination to enter into, any merger, sale or other business combination transaction, or an agreement therefor, pursuant to which the outstanding shares of capital stock of the Company would be converted into cash, other
consideration or securities of another person or 13D Group or 50% or more of the then outstanding shares of capital stock of the Company would be owned by persons other than the then current holders of shares of capital stock of the Company, or
which would result in all or a substantial portion of the Company’s assets being sold to any person or 13D Group. 
 (iv)
“Voting Securities” shall mean at any time shares of any class of capital stock of the Company which are then entitled to vote generally in the election of directors. 

(v) “13D Group” shall mean, with respect to the Voting Securities of the Company, any group of persons formed for the
purpose of acquiring, holding, voting or disposing of such Voting Securities which would be required under Section 13(d) of the Exchange Act and the rules and regulations thereunder to file a statement on Schedule 13D with the Commission
as a “person” within the meaning of Section 13(d)(3) of the Exchange Act if such group beneficially owned Voting Securities representing more than 5% of the total combined voting power of all such Voting Securities then outstanding.

 (b) Restriction Period No Sell. The Investor agrees that during the Restriction Period, neither the Investor nor any of its
Affiliates shall offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of in any manner, either directly or indirectly (“Sale” or “Sell”), any Shares, or any
securities of the Company issued as a dividend or distribution on, or involving a recapitalization or reorganization with respect to, such Shares (collectively, “Covenant Shares”), other than transfers of securities between and
among the Company and any one or more of its Affiliates. Without limiting the Company’s obligations under Section 7.2, the Company shall use commercially reasonable efforts to permit the Shares to be eligible for clearance and settlement
through the facilities of The Depository Trust Company immediately following the termination of the Restriction Period. 
 (c) Occurrence
of Significant Event. The restrictions contained in Section 6.1(b) shall be suspended and shall not apply to or otherwise restrict the Investor’s actions in respect of the Company’s securities for so long as a Significant Event
has occurred and is continuing. 
 6.2 Invalid Transfers. Any sale, assignment or other transfer of Covenant Shares by the
Investor or any of its Affiliates, as applicable, contrary to the provisions of this Section 6 shall be null and void, and the transferee shall not be recognized by the Company as the holder or owner of the Covenant Shares sold, assigned, or
transferred for any purpose (including, without limitation, voting or dividend rights), unless and until the Investor or such Affiliate, as applicable, has satisfied the requirements of this Section 6 with respect to such sale. The Investor
shall provide the Company 

  
 10 

 Confidential 
  

 
with written evidence that such requirements have been met or waived, prior to it or its Affiliates consummating any sale, assignment or other transfer of securities, and no Covenant Shares shall
be transferred on the books of the Company until such written evidence has been received by the Company from the Investor. The Company, or, at the instruction of the Company, the transfer agent of the Company, may place a legend on any certificate
representing Covenant Shares stating that such shares are subject to the restrictions contained in this Agreement; provided that the Company shall remove, or instruct the transfer agent to remove, such legend upon the expiration of the Restriction
Period. Upon delivery by the Investor of the written evidence required above, the Company agrees to facilitate the timely preparation and delivery (but in no event longer than three (3) trading days) of certificates representing the Covenant
Shares to be sold by the Investor or any Affiliate free of any restrictive legends and in such denominations and registered in such names as the Investor or such Affiliate may request in connection with such sale. 

6.3 Performance by Affiliates. The Investor shall remain responsible for and guarantee its Affiliates’ performance in
connection with this Agreement, and shall cause each such Affiliate to comply fully with the provisions of this Agreement in connection with such performance. The Investor hereby expressly waives any requirement that the Company exhaust any right,
power or remedy, or proceed directly against such an Affiliate, for any obligation or performance hereunder, prior to proceeding directly against the Investor. 

SECTION 7 
 Resales

 7.1 Rule 144 Reporting. With a view to making available to the Investor the benefits of certain rules and regulations
of the Commission which may permit the sale of the Shares to the public without registration, the Company agrees to use commercially reasonable efforts to: 

(a) Make and keep public information available, as those terms are understood and defined in Rule 144 promulgated under the Securities Act;

 (b) File with the Commission in a timely manner all reports and other documents required of the Company under the Exchange Act; and 

(c) Furnish the Investor forthwith upon request (i) a written statement by the Company as to its compliance with the public information
requirements of said Rule 144, (ii) a copy of the most recent annual or quarterly report of the Company, and (iii) such other reports and documents as may be reasonably requested in availing the Investor of any rule or regulation of the
Commission permitting the sale of any such securities without registration. 

  
 11 

 Confidential 
  

 7.2 Restrictive Legend. The certificates representing the Shares, when issued,
will bear a restrictive legend in substantially the following form: 
 “THE SECURITIES EVIDENCED OR CONSTITUTED HEREBY HAVE BEEN ISSUED
WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) AND MAY NOT BE SOLD, OFFERED FOR SALE, TRANSFERRED, PLEDGED OR HYPOTHECATED WITHOUT REGISTRATION UNDER THE ACT UNLESS EITHER (i) THE COMPANY HAS RECEIVED AN
OPINION OF COUNSEL, IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY, TO THE EFFECT THAT REGISTRATION IS NOT REQUIRED IN CONNECTION WITH SUCH DISPOSITION OR (ii) THE SALE OF SUCH SECURITIES IS MADE PURSUANT TO SECURITIES AND
EXCHANGE COMMISSION RULE 144.” 
 The legend set forth in this Section 7.2 and the related notation in the Company’s stock
books shall be removed and the Company shall issue a certificate without such legend or any other legend to the holder of the Shares or issue to such holder by electronic delivery at the applicable balance account at the Depository Trust Company, if
(i) the Shares are registered for resale under the Securities Act, (ii) the Shares are sold or transferred in compliance with to Rule 144, or (iii) the Shares are eligible for sale under Rule 144, without the requirement for the
Company to be in compliance with the current public information required under Rule 144. Following Rule 144 becoming available for the resale of Shares, without the requirement for the Company to be in compliance with the current public information
required under Rule 144, the Company shall (at the Company’s expense), upon the written request of Investor, cause its counsel to issue to the Company’s transfer agent a legal opinion authorizing the issuance of a certificate representing
the Shares without any restrictive or other legends, if requested by such transfer agent. 
 SECTION 8 

Indemnification 
 Each
party (an “Indemnifying Party”) hereby indemnifies and holds harmless the other party, such other party’s respective officers, directors, employees, consultants, representatives and advisers, and any and all Affiliates (as
defined in Section 6.1(a)) of the foregoing (each of the foregoing, an “Indemnified Party”) from and against all losses, liabilities, costs, damages and expense (including reasonable legal fees and expenses) (collectively,
“Losses”) suffered or incurred by any such Indemnified Party to the extent arising from, connected with or related to (i) breach of any representation or warranty of such Indemnifying Party in this Agreement; and
(ii) breach of any covenant or undertaking of any Indemnifying Party in this Agreement. If an event or omission (including, without limitation, any claim asserted or action or proceeding commenced by a third party) occurs which an Indemnified
Party asserts to be an indemnifiable event pursuant to this Section 8, the Indemnified Party will provide written notice to the Indemnifying Party, setting forth the nature of the claim and the basis for indemnification under this Agreement.
The Indemnified Party will give such written notice to the Indemnifying Party immediately after it becomes aware of the existence of any such event or occurrence. Such notice will be a condition precedent to any obligation of the Indemnifying Party
to act under this Agreement but will not relieve it of its obligations under the indemnity except to the extent that the failure to provide prompt notice as provided in this Agreement prejudices the Indemnifying Party with respect to the
transactions contemplated by this Agreement and to the defense of the liability. In case any such action is brought by a third party against any Indemnified Party and it notifies the Indemnifying Party of the commencement thereof, the Indemnifying
Party will be entitled to participate therein and, to the 

  
 12 

 Confidential 
  

 
extent that it wishes, to assume the defense and settlement thereof with counsel reasonably selected by it and, after notice from the Indemnifying Party to the Indemnified Party of such election
so to assume the defense and settlement thereof, the Indemnifying Party will not be liable to the Indemnified Party for any legal expenses of other counsel or any other expenses subsequently incurred by such Indemnified Party in connection with the
defense thereof, provided, however, that an Indemnified Party shall have the right to employ separate counsel at the expense of the Indemnifying Party if (i) the employment thereof has been specifically authorized in writing by the Indemnifying
Party; or (ii) representation of both parties by the same counsel would be inappropriate due to actual or potential conflicts of interests between such parties (which such judgment shall be made in good faith after consultation with counsel).
The Indemnified Party agrees to cooperate fully with (and to provide all relevant documents and records and make all relevant personnel available to) the Indemnifying Party and its counsel, as reasonably requested, in the defense of any such
asserted claim at no additional cost to the Indemnifying Party. No Indemnifying Party will consent to the entry of any judgment or enter into any settlement with respect to any such asserted claim without the prior written consent of the Indemnified
Party, not to be unreasonably withheld or delayed, (a) if such judgment or settlement does not include as an unconditional term thereof the giving by each claimant or plaintiff to each Indemnified Party of a release from all liability in
respect to such claim or (b) if, as a result of such consent or settlement, injunctive or other equitable relief would be imposed against the Indemnified Party or such judgment or settlement could materially and adversely affect the business,
operations or assets of the Indemnified Party. No Indemnified Party will consent to the entry of any judgment or enter into any settlement with respect to any such asserted claim without the prior written consent of the Indemnifying Party, not to be
unreasonably withheld or delayed. If an Indemnifying Party makes a payment with respect to any claim under the representations or warranties set forth herein and the Indemnified Party subsequently receives from a third party or under the terms of
any insurance policy a sum in respect of the same claim, the receiving party will repay to the other party such amount that is equal to the sum subsequently received. 

SECTION 9 
 Miscellaneous

 9.1 Governing Law. This Agreement shall be governed in all respects by the laws of the State of New York as applied to
agreements entered into and performed entirely in the State of New York by residents thereof. 
 9.2 Survival. The
representations, warranties, covenants and agreements made herein shall survive any investigation made by the Investor and the Closing. 

9.3 Successors, Assigns. Except as otherwise provided herein, the provisions hereof shall inure to the benefit of, and be
binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto. This Agreement may not be assigned by either party without the prior written consent of the other; except that either party may assign this Agreement
to an Affiliate (as defined in Section 6.1(a)) of such party or to any third party that acquires all or substantially all of such party’s business, whether by merger, sale of assets or otherwise. 

  
 13 

 Confidential 
  

 9.4 Notices. All notices and other communications required or permitted
hereunder shall be in writing and shall be sent by facsimile (receipt confirmed) or mailed by registered or certified mail, postage prepaid, return receipt requested, or otherwise delivered by hand or by messenger, addressed 

if to the Investor, at the following address: 

RPI Finance Trust 
 c/o RP
Management, LLC 
 110 East 59th St, 33rd Floor 

New York, NY 10022 
 Attention:
George Lloyd 
 Telephone: (212) 883-2280 

E-mail: glloyd@royaltypharma.com 

Facsimile: (212) 883-2260 

with a copy to: 
 Goodwin Procter
LLP 
 100 Northern Avenue 

Boston, Massachusetts 02210 

Attention: Arthur McGivern 

Telephone: 617-570-1971 

Facsimile: (617) 523-1231 

Email: AMcGivern@goodwinlaw.com 

if to the Company, at the following address: 

Cytokinetics, Incorporated 
 280 E
Grand Ave 
 South San Francisco, CA 94080 

Attention: General Counsel 

Facsimile: (650) 624-3010 

with a copy to: 
 Cooley LLP 

3175 Hanover St. 
 Palo Alto, CA
94304 
 Attention: Michael Tenta 

Telephone: (650) 843-5636 

Facsimile: (650) 849-7400 

Email: mtenta@cooley.com 

  
 14 

 Confidential 
  

 or at such other address as one party shall have furnished to the other party in writing. All notices and
communications under this Agreement shall be deemed to have been duly given (i) when delivered by hand, if personally delivered, (ii) when received by a recipient, if sent by email, (iii) when sent, if sent by facsimile, with an
acknowledgement of sending being produced by the sending facsimile machine or (iv) one Business Day following sending within the United States by overnight delivery via commercial one-day overnight courier service. 

9.5 Expenses. Each of the Company and the Investor shall bear its own expenses and legal fees incurred on its behalf with
respect to this Agreement and the transactions contemplated hereby. 
 9.6 Finder’s Fees. Each of the Company and the
Investor shall indemnify and hold the other harmless from any liability for any commission or compensation in the nature of a finder’s fee, placement fee or underwriter’s discount (including the costs, expenses and legal fees of defending
against such liability) for which the Company or the Investor, or any of its respective partners, employees, or representatives, as the case may be, is responsible. 

9.7 Counterparts. This Agreement may be executed in counterparts, each of which shall be enforceable against the party actually
executing the counterpart, and all of which together shall constitute one instrument. 
 9.8 Severability. In the event that
any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision; provided that no such severability shall
be effective if it materially changes the economic benefit of this Agreement to any party. 
 9.9 Entire Agreement. This
Agreement and the Royalty Purchase Agreement, including the exhibits and schedules attached hereto and thereto, constitute the full and entire understanding and agreement among the parties with regard to the subjects hereof and thereof. No party
shall be liable or bound to any other party in any manner with regard to the subjects hereof or thereof by any warranties, representations or covenants except as specifically set forth herein or therein. 

9.10 Waiver. The failure of either party to assert a right hereunder or to insist upon compliance with any term or condition of
this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party. None of the terms, covenants and conditions of this Agreement can be waived except by the
written consent of the party waiving compliance. 
 9.11 Trustee Capacity of Wilmington Trust Company. Notwithstanding
anything contained herein to the contrary, it is expressly understood and agreed by the parties hereto that (i) this Agreement is executed and delivered by Wilmington Trust Company, not individually or personally but solely in its trustee
capacity, in the exercise of the powers and authority conferred and vested in it under the trust deed of the Investor, (ii) each of the representations, undertakings and agreements herein made on the part of the Investor is made and intended
not as a personal representation, undertaking and agreement by Wilmington Trust Company but is made and intended 

  
 15 

 Confidential 
  

 
for the purpose of binding only the Investor and (iii) under no circumstances shall Wilmington Trust Company be personally liable for the payment of any indebtedness or expenses of the
Investor or be liable for the breach or failure of any obligation, representation, warranty or covenant made or undertaken by the Investor under this Agreement or any related documents 

[SIGNATURE PAGES FOLLOW] 

  
 16 

 Confidential 
  

 IN WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the
date first set forth above. 
  

			
	CYTOKINETICS, INCORPORATED
		
	By:	 	/s/ Robert I. Blum
	Name:	 	Robert I. Blum
	Title:	 	President and CEO

  

			
	RPI FINANCE TRUST
		
	By:	 	Wilmington Trust Company, not in its individual capacity but solely in its capacity as owner trustee
		
	By:	 	/s/ Beverly D. Capers
	Name:	 	Beverly D. Capers
	Title:	 	Assistant Vice President

  

 Confidential 
  

 Schedule A 

The Investor is an institutional “accredited investor” as defined in Rule 501(a) of Regulation D of the Securities Act. 

  

 Confidential 
  

 EXHIBIT A 

Schedule of Exceptions 
 None.PROMISSORY NOTE

 

EXHIBIT 10.1

SECURED PROMISSORY NOTE

$500,000.00

Issuance Date: February 28, 2017

Maturity Date: December 15, 2017

FOR VALUE RECEIVED, Ecosphere Technologies, Inc. (the “Company”), a Delaware corporation, and Sea of Green Systems, Inc. (“SOGS”), a Florida corporation and subsidiary of the Company, jointly and severally, hereby promise to pay to the order of Brisben Water Solutions LLC or its assigns (the “Holder”), the principal sum of $500,000.00 (or such lesser amounts actually advanced) together with interest at 10% per annum, on the basis of a 360-day year, on the principal amount advanced. Such principal amounts may be advanced prior to the Maturity Date in one or more tranches, in the discretion of the Holder, up to a total aggregate amount of $500,000.00. The principal amount advanced under each tranche shall bear interest from the date of advance. This note (the “Note”) is issued in addition to, and not in replacement or modification of, that certain Amended, Restated and Consolidated Convertible Note issued September 12, 2016 and that certain Secured Promissory Note issued October 5, 2017 (the “Prior Notes”).

Interest and the principal of this Note shall be due and payable on the Maturity Date (defined above).

While in default, this Note (or the amount thereof in default) shall bear interest at the rate of 18% per annum or such maximum rate of interest allowable under the laws of the State of Florida. Payments shall be made in lawful money of the United States. This Note shall be prepaid upon the sale by the Company of any part of the Collateral (as defined below) and shall be repaid upon occurrence of any events requiring repayment under the Security Agreement (defined below).  The Company shall give the Holder written notice of any sale of any part of the Collateral at least 30 days prior to such sale.

1.

Conversion to Common Stock of Sea of Green Systems, Inc.

(a)

Amounts of principal and accrued interest under the Note shall be convertible into shares of common stock of Sea of Green Systems, Inc., a Florida corporation (“SOGS”), which are presently held by the Company. The number of shares of common stock issuable upon a conversion of this Note shall be determined by dividing: (i) the amounts being converted under this Note by (ii) $0.046614483 per share, subject to equitable adjustment for stock splits, stock dividends, combinations and similar events. Any fractional shares otherwise issuable upon a conversion shall be rounded up to the next whole share.

(b)

To convert this Note into SOGS common stock on any date (a “Conversion Date”), the Holder shall: (i) transmit by email (or otherwise deliver), for receipt on or prior to 11:59 p.m., New York time, on such date, a copy of an executed notice of conversion in the form attached hereto as Exhibit A (the “Conversion Notice”) to the Company, and (ii) surrender this Note to a common carrier for delivery to the Company as soon as practicable on or following such date (or an indemnification undertaking with respect to this Note in the case of its loss, theft or destruction).  On or before the second business day following the date of receipt of a Conversion Notice, the Company shall confirm that it has issued to the Holder the number of shares of common stock to which the Holder shall be entitled, and shall 

1

 

return to the Holder a new Note with respect to the portion of the original Note which was not converted.  The person or persons entitled to receive the common stock issuable upon a conversion of this Note shall be treated for all purposes as the record holder or holders of such common stock on the Conversion Date.

2.

Collateral.  This Note and the Prior Notes shall be secured by the Collateral, as defined in the Security Agreement between the Company and the Holder, dated as of the date hereof, which replaces and supersedes all prior security agreements entered into between the Company and the Holder prior to the date hereof (the “Security Agreement”). 

3.

Event of Default.  In the event of any failure to pay this Note or the Prior Notes when due; or the Company shall be in breach of or default under any agreement with the Holder; or the Company shall sell all or substantially all of its assets, or dissolve, liquidate, or wind up its affairs, or enter into an agreement to do any of the foregoing; or the Company shall commence any case, proceeding or other action under any existing or future law of any jurisdiction, domestic or foreign, relating to bankruptcy, insolvency, reorganization, or relief of debtors, seeking to have an order for relief entered with respect to it, or seeking to adjudicate it as bankrupt or insolvent, or seeking reorganization, arrangement, adjustment, winding-up, liquidation, dissolution, composition or other relief with respect to its debts, or seeking appointment of a receiver, custodian, trustee or other similar official for it or for all or any substantial part of its assets; or there shall be commenced against the Company, any case, proceeding or other action which results in the entry of an order for relief or any such adjudication or appointment remains undismissed, undischarged or unbonded for a period of 30 days after service upon the Company; or there shall be commenced against the Company, any case, proceeding or other action seeking issuance of a warrant of attachment, execution, restraint or similar process against all or any substantial part of its assets which results in the entry of an order for any such relief which shall not have been vacated, discharged, or stayed or bonded pending appeal within 10 days from the entry thereof after service upon the Company; or the Company shall make an assignment for the benefit of creditors; or the Company shall take any action indicating its consent to, approval of, or acquiescence in, or in furtherance of, any of the foregoing; or the Company or any of its subsidiaries shall fail to pay any indebtedness for borrowed money to any third party when due; then, or any time thereafter during the continuance of any of such events, the entire unpaid balance of this Note then outstanding, together with accrued interest thereon, if any, shall be and become immediately due and payable without notice of demand by Holder.

4.

Investment Intent.  The Holder, by acceptance of this Note, warrants and represents that it is acquiring this Note and, upon conversion shares of SOGS common stock, for its own account, for investment and not with a view to, or for resale in connection with, the distribution thereof.  The Holder has no present intention of reselling or distributing it after any period of time.  The acquisition of this Note for investment is consistent with Holder’s financial needs.

5.

Miscellaneous.

(a)

All makers and endorsers now or hereafter becoming parties hereto jointly and severally waive demand, presentment, notice of non-payment and protest. 

(b)

This Note may not be changed or terminated orally, but only with an agreement in writing, signed by the parties against whom enforcement of any waiver, change, modification, or discharge is sought with such agreement being effective and binding only upon attachment hereto.

2

 

(c)

This Note and the rights and obligations of the Holder and of the undersigned shall be governed and construed in accordance with the laws of the State of Delaware.

(d)

Any action brought by either party against the other concerning this Note shall be brought only in the state or federal courts of Florida and venue shall be in the County of Martin or the Southern District of Florida.  The parties to this Note hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens.

(e)

In the event that there is any controversy or claim arising out of or relating to this Note, or to the interpretation, breach or enforcement thereof, and any action or proceeding is commenced to enforce the provisions of this Note, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and expenses (including such fees and costs on appeal).

(f)

Upon any endorsement, assignment, or other transfer of this Note by the Holder or by operation of law, the term “Holder,” as used herein, shall mean such endorsee, assignee, or other transferee or successor to the Holder, then becoming the holder of this Note.  This Note shall inure to the benefit of the Holder and its successors and assigns and shall be binding upon the undersigned and their successors and assigns.  

(g)

In the event that any interest paid on this Note is deemed to be in excess of the then legal maximum rate, then that portion of the interest payment representing an amount in excess of the then legal maximum rate shall be deemed a payment of principal and applied against the principal of this Note, and any surplus thereafter shall immediately be refunded to the Company.

(h)

To the extent permitted by law, any reproduction of this Note shall be admissible in evidence as the original itself in any judicial or administrative proceeding (whether or not the original is in existence and whether or not such reproduction was made by Holder or the Company or SOGS in the regular course of business) and that, to the extent permitted by law, any enlargement, facsimile or further reproduction of such reproduction shall likewise be admissible in evidence.

6.

Modification of Prior Notes.  The Prior Notes are modified to add as an Event of Default thereof any failure to pay this Note when due. The Holder may surrender the Prior Notes in exchange for a new Note evidencing such modification.

7.

Covenant Against Section 12 Registration.  While any sums remain unpaid and outstanding under this Note, the Company and SOGS shall not register the common stock of SOGS under Section 12 of the Securities Exchange Act of 1934 (the “Exchange Act”) unless required by law, without the prior written consent of the Holder, which will not be unreasonably withheld. 

8.

Blocker.  Notwithstanding anything to the contrary in this Note, if at the time of conversion the common stock of SOGS is registered under Section 12 of the Exchange Act, this Note shall not be convertible by Holder, and the Company and SOGS shall not effect any such conversion, to the extent (but only to the extent) that giving effect to such conversion or other issuance hereunder Holder (together with its affiliates and members of any group of which Holder is a part) would beneficially own in excess of 9.99% of all  common stock of SOGS outstanding at such time (the “Blocker”).  For purposes of this Section, beneficial ownership shall be determined in accordance with Section 13(d) of the 

3

 

Exchange Act.  The Blocker may be waived only upon (i) Holder providing the Company with 61 days notice that Holder desires to waive the Blocker for any or all of the shares and (ii) approval of the waiver by the Company.

[Signature Page Follows]

4

 

IN WITNESS WHEREOF, the Company and SOGS have caused this Note to be executed as of the date aforesaid.

			
	 
	COMPANY:

	 
	 
	 

	 
	Ecosphere Technologies, Inc.,

	 
	a Delaware corporation

	 
	 
	 

	 
	 
	 

	 
	 
	 

	 
	 
	 

	 
	By:  

	/s/ Dennis McGuire

	 
	 
	Dennis McGuire,

	 
	 
	Chief Executive Officer

	 
	 
	 

	 
	SOGS:

	 
	 
	 

	 
	Sea of Green Systems, Inc.,

	 
	a Florida corporation

	 
	 
	 

	 
	 
	 

	 
	 
	 

	 
	 
	 

	 
	By:  

	/s/ Cory McGuire

	 
	 
	Cory McGuire,

	 
	 
	Chief Executive Officer

5

 

EXHIBIT A

Conversion Notice

Reference is made to the Convertible Note (the “Note”) issued to the undersigned by Ecosphere Technologies, Inc. and Sea of Green Systems, Inc. In accordance with and pursuant to the Note, the undersigned hereby elects to convert, in whole or in part (as applicable), the principal and any accrued interest of the Note into common stock of Sea of Green Systems, Inc., as of the date specified below.

												
	Date of Conversion:

	 

	Please confirm the following information:

	Conversion Price:

	 

	Principal and accrued interest to be converted (if partial):

	 

	Number of shares of common stock to be issued:

	 

	Please issue the common stock into which the Note is being converted in the following name and to the following address:

	Issue to:

	 

	 
	 

	 
	 

	Email Address:

	 

	Authorization:

	 

	By:

	 

	Title:

	 

	Dated:

	 

	Account Number:

	 

	  (if electronic book entry transfer)

	 

	Transaction Code Number:

	 

	  (if electronic book entry transfer)

	 

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}]]